Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
ConclusionHyperprogression is rare in melanoma patients treated with immune checkpoint inhibitors. Our data question if hyperprogression really is a biological entity in metastatic melanoma.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Academia | Allergy & Immunology | Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Netherlands Health | PET Scan | Skin Cancer | Study